166 related articles for article (PubMed ID: 23142657)
1. Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts.
Borgan E; Lindholm EM; Moestue S; Mælandsmo GM; Lingjærde OC; Gribbestad IS; Børresen-Dale AL; Engebraaten O; Sørlie T
Mol Oncol; 2013 Feb; 7(1):130-42. PubMed ID: 23142657
[TBL] [Abstract][Full Text] [Related]
2. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.
Lindholm EM; Kristian A; Nalwoga H; Krüger K; Nygård S; Akslen LA; Mælandsmo GM; Engebraaten O
Mol Oncol; 2012 Aug; 6(4):418-27. PubMed ID: 22521242
[TBL] [Abstract][Full Text] [Related]
3. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models.
Moestue SA; Borgan E; Huuse EM; Lindholm EM; Sitter B; Børresen-Dale AL; Engebraaten O; Maelandsmo GM; Gribbestad IS
BMC Cancer; 2010 Aug; 10():433. PubMed ID: 20716336
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
[TBL] [Abstract][Full Text] [Related]
5. Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations.
Lindholm EM; Krohn M; Iadevaia S; Kristian A; Mills GB; Mælandsmo GM; Engebraaten O
Clin Cancer Res; 2014 Jan; 20(2):404-12. PubMed ID: 24192926
[TBL] [Abstract][Full Text] [Related]
6. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
7. Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.
Grinde MT; Skrbo N; Moestue SA; Rødland EA; Borgan E; Kristian A; Sitter B; Bathen TF; Børresen-Dale AL; Mælandsmo GM; Engebraaten O; Sørlie T; Marangoni E; Gribbestad IS
Breast Cancer Res; 2014 Jan; 16(1):R5. PubMed ID: 24447408
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
Jahangiri A; De Lay M; Miller LM; Carbonell WS; Hu YL; Lu K; Tom MW; Paquette J; Tokuyasu TA; Tsao S; Marshall R; Perry A; Bjorgan KM; Chaumeil MM; Ronen SM; Bergers G; Aghi MK
Clin Cancer Res; 2013 Apr; 19(7):1773-83. PubMed ID: 23307858
[TBL] [Abstract][Full Text] [Related]
9. 13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns.
Grinde MT; Moestue SA; Borgan E; Risa Ø; Engebraaten O; Gribbestad IS
NMR Biomed; 2011 Dec; 24(10):1243-52. PubMed ID: 21462378
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Sweep FC; Geurts-Moespot A; Engelhardt MS; van der Graaf WT; Oyen WJ; van Laarhoven HW
Mol Pharm; 2014 Nov; 11(11):4249-57. PubMed ID: 25294389
[TBL] [Abstract][Full Text] [Related]
11. Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts.
Esmaeili M; Bathen TF; Engebråten O; Mælandsmo GM; Gribbestad IS; Moestue SA
Magn Reson Med; 2014 Jun; 71(6):1973-81. PubMed ID: 23878023
[TBL] [Abstract][Full Text] [Related]
12. In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts.
Esmaeili M; Moestue SA; Hamans BC; Veltien A; Kristian A; Engebråten O; Maelandsmo GM; Gribbestad IS; Bathen TF; Heerschap A
J Magn Reson Imaging; 2015 Mar; 41(3):601-9. PubMed ID: 24532410
[TBL] [Abstract][Full Text] [Related]
13. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
15. Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.
Kristian A; Revheim ME; Qu H; Mælandsmo GM; Engebråten O; Seierstad T; Malinen E
Acta Oncol; 2013 Oct; 52(7):1566-72. PubMed ID: 23984812
[TBL] [Abstract][Full Text] [Related]
16. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
[TBL] [Abstract][Full Text] [Related]
17. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
[TBL] [Abstract][Full Text] [Related]
18. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
Inoue S; Hartman A; Branch CD; Bucana CD; Bekele BN; Stephens LC; Chada S; Ramesh R
Mol Ther; 2007 Feb; 15(2):287-94. PubMed ID: 17235306
[TBL] [Abstract][Full Text] [Related]
19. The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.
Gómez-Miragaya J; Morán S; Calleja-Cervantes ME; Collado-Sole A; Paré L; Gómez A; Serra V; Dobrolecki LE; Lewis MT; Diaz-Lagares A; Eroles P; Prat A; Esteller M; González-Suárez E
Mol Cancer Res; 2019 Oct; 17(10):2063-2076. PubMed ID: 31320385
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for antitumor activity of bevacizumab in gastric cancer models.
Yamashita-Kashima Y; Fujimoto-Ouchi K; Yorozu K; Kurasawa M; Yanagisawa M; Yasuno H; Mori K
BMC Cancer; 2012 Jan; 12():37. PubMed ID: 22273502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]